Safety and Efficacy of 10 kHz Spinal Cord Stimulation for the Treatment of Refractory Chronic Migraine: A Prospective Long-Term Open-Label Study
Autor: | Adnan Al-Kaisy, Stefano Palmisani, Angela Santos, Anand Rotte, Giorgio Lambru, Samuel Wesley, David Pang, Roy Carganillo |
---|---|
Rok vydání: | 2022 |
Předmět: |
Adult
Migraine Disorders medicine.medical_treatment 03 medical and health sciences 0302 clinical medicine Chronic Migraine Refractory Quality of life Humans Medicine Prospective Studies Prospective cohort study Adverse effect Neurostimulation Spinal Cord Stimulation business.industry General Medicine medicine.disease Neuromodulation (medicine) Treatment Outcome Anesthesiology and Pain Medicine Neurology Migraine Anesthesia Quality of Life Neurology (clinical) business 030217 neurology & neurosurgery |
Zdroj: | Neuromodulation: Technology at the Neural Interface. 25:103-113 |
ISSN: | 1094-7159 |
DOI: | 10.1111/ner.13465 |
Popis: | BACKGROUND Refractory chronic migraine (rCM) is a highly disabling condition for which novel safe and effective treatments are needed. Safety and long-term efficacy of paresthesia-free high cervical 10 kHz spinal cord stimulation (SCS) were here prospectively evaluated for the treatment of rCM. MATERIALS AND METHODS Twenty adults with rCM (mean numbers of preventive treatments failed: 12.2 ± 3.1) were enrolled in this single-center, open-label, prospective study and implanted with a 10 kHz SCS system (Senza™ system, Nevro Corp.), with the distal tip of the lead(s) positioned epidurally at the C2 vertebral level. Safety and effectiveness outcomes, such as adverse events, headache and migraine reductions, responder rates, Migraine Disability Assessment (MIDAS), Headache Impact Test-6 (HIT-6), and Migraine-Specific Quality-of-Life (MSQ), were captured up to 52 weeks after implantation. RESULTS Compared to baseline, at 52 weeks postimplantation, there was a significant reduction of mean monthly migraine days (MMD) by 9.3 days (p |
Databáze: | OpenAIRE |
Externí odkaz: |